Clinical Ink Implements Fee Structure Changes in Face of COVID-19
Clinical Ink, a global clinical trial technology company, has announced a wide-ranging Study Assurance Program to minimize financial impact of the disruption from COVID-19 on new and existing clinical trials. Because of the effect of global quarantines has dramatically impacted new patient recruitment and has substantially changed how existing patients participate in ongoing clinical trials, the Program addresses change order waivers, fees related to BYOD ePRO project management waived, as well as additional provisions.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
